We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Share this :
Print
Cell Signaling Androgen Receptor (Ar-V7 Specific) Antibody
Cell Signaling Androgen Receptor (Ar-V7 Specific) Antibody - CSIG (Additional S&H or Hazmat Fees May Apply)
List Price
$377.00
Your Price
$377.00
HOW MUCH YOU SAVE:
0.00 %
| NETA PART: | CSIG-68492S |
| MFG.PART: | 68492S |
| UNSPSC: | 12352203 |
| Manufacturer: | Cell Signaling |
| Size | 100 µl |
| Reactivity | H |
| Sensitivity | Endogenous |
| Molecular Weight (kDa) | 80 |
| Source/Isotype | Rabbit |
| Application/Dilution | {Western Blotting: 1:1000} |
| Storage | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. |
| Specificity/Sensitivity | Androgen Receptor (AR-V7 Specific) Antibody recognizes endogenous levels of total AR-V7 protein. This antibody does not cross-react with full-length AR protein. |
| Species Reactivity | Human |
| Source/Purification | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu639 of human androgen receptor (V7 isoform) protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Background | Androgen receptor (AR), a zinc finger transcription factor belonging to the nuclear receptor superfamily, is activated by phosphorylation and dimerization upon ligand binding (1). This promotes nuclear localization and binding of AR to androgen response elements in androgen target genes. Research studies have shown that AR plays a crucial role in several stages of male development and the progression of prostate cancer (2,3).The AR3 or AR-V7 isoform, which lacks the typical ligand binding domain, is created through the alternative splicing of cryptic exons (4-5). AR-V7 is frequently expressed in castration-resistant prostate cancer (CRPC) and while dependent on the activity of the full-length androgen receptor (AR-FL), AR-V7 can activate a completely distinct transcriptional program (6-8). While enzalutamide and abiraterone have been beneficial in treating CRPC through the ligand binding domain of AR-FL, resistance in patients has been shown to be associated with AR-V7 detection in circulating tumor cells (9-12). Studies probing into mechanisms of overcoming this resistance are currently being explored and may help in stratifying patient populations for more personalized therapies (13-15). |
| SKU | CSIG-68492S |
|---|---|
| Supplier Part Number | 68492S |
| UM | EA |
| UNSPSC | 12352203 |
| Manufacturer | Cell Signaling |
| MSDS URL | https://www.cellsignal.com/contents/technical/safety-data-sheet-(sds)/resources-safety-data-sheets |
| Temperature | -20C |
| ProductLine | CSIG |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.00 |
| Lead Time | 5 Business Days |